Replies to post #117612 on Biotech Values

[jq1234]

Is it safe to say that you feel that BIOD's ultrafast acting insulin is sufficiently differentiated from the fast acting insulins to be able to succesfully compete against any generic fast acting insulins that could be on the market at the time BIOD's product is ready for commercialization?

I'd say yes. Just like fast insulin vs regular insulin.

Do you feel that HALO's one-year advantage is any kind of issue for BIOD? I'm not sure exactly where MNKD stands in timing in this race given their recent setbacks. Also, do you see the products from each of these three companies as reasonably comparable or does one clearly stand out from the other?

I don't think much of MNKD inhaled insulin. I am not comfortable with inhaled insulin at this point. HALO's ultrafast insulin approach is different from BIOD's. BIOD's is standing alone ultrafast insulin while HALO's is PH20 addition to existing either regular or fast insulin lispro and aspart, thus HALO's PH20 could extend lispro and/or aspart patent life for big pharma while BIOD will be new formulation. Insulin is a big market and growing, enough space for all. Both ultrafast insulin could be mixed with existing insulins, regular/long acting or fast, to produce something similar to Novolog Mix 70/30.

Regardless, the $60M market cap is tiny and you can't expect a company with that kind of valuation to be in a perfect situation.

Exactly.